EYP 002

Drug Profile

EYP 002

Alternative Names: EYP002

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ENYO Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Mitochondrial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 04 Dec 2017 ENYO Pharma plans to file an IND application with the US FDA in USA for Influenza virus infection by the end of 2018 (ENYO pharma pipeline, December 2017)
  • 28 Nov 2017 Preclinical trials in Influenza virus infections in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top